Emcure Pharmaceuticals Limited IPO
Emcure Pharmaceuticals Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹960–₹1,008 per share to raise ₹1,952 crore. The issue was subscribed 67.87× overall (QIBs 195.83×, NIIs 48.32×, retail 7.21×). It listed on 10 Jul 2024 at ₹1,325 and closed its first day at ₹1,359, a listing gain of +34.8% versus the ₹1,008 issue price. It now trades around ₹1,872 (+85.7% versus the issue price).
Frequently asked questions
- How many times was the Emcure Pharmaceuticals Limited IPO subscribed?
- The Emcure Pharmaceuticals Limited IPO was subscribed 67.87× overall — 195.83× in the QIB category, 48.32× among non-institutional investors, 7.21× in retail.
- What were the Emcure Pharmaceuticals Limited IPO listing gains?
- Emcure Pharmaceuticals Limited listed on 10 Jul 2024 at ₹1,325, closing its first day at ₹1,359 — a listing gain of +34.8% versus the ₹1,008 issue price.
- What were the retail allotment odds for the Emcure Pharmaceuticals Limited IPO?
- Retail was subscribed 7.21×, so a single-lot application had roughly a 13.9% chance of allotment (about 1 in 7), and allotment was finalised on 8 Jul 2024.
- What was the price band and lot size of the Emcure Pharmaceuticals Limited IPO?
- The price band was ₹960–₹1,008 per share, with a minimum lot of 14 shares (₹14,112 at the upper band).
- Who were the registrar and lead manager for the Emcure Pharmaceuticals Limited IPO?
- Link Intime India Private Limited was the registrar, and Axis Capital was the book-running lead manager.